These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36342356)

  • 1. Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease.
    Du K; Huang X; Peng A; Yang Q; Chen D; Zhang J; Qi R
    Mol Pharm; 2023 Jan; 20(1):159-171. PubMed ID: 36342356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyurethane Nanoparticle-Loaded Fenofibrate Exerts Inhibitory Effects on Nonalcoholic Fatty Liver Disease in Mice.
    Cao YN; Baiyisaiti A; Wong CW; Hsu SH; Qi R
    Mol Pharm; 2018 Oct; 15(10):4550-4557. PubMed ID: 30188729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice.
    Cao Y; Xu L; Chen C; Wang Y; Zhang Q; Qi R
    Nanomedicine; 2016 Nov; 12(8):2449-2458. PubMed ID: 27438910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
    Wang X; Wang J; Ying C; Xing Y; Su X; Men K
    BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
    Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
    Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
    Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
    J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
    Jiang S; Uddin MJ; Yu X; Piao L; Dorotea D; Oh GT; Ha H
    Diabetes Metab J; 2022 Nov; 46(6):829-842. PubMed ID: 35746892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
    Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic
    Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH
    Elife; 2021 Dec; 10():. PubMed ID: 34964438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanism of Triclosan in the Treatment of Nonalcoholic Fatty Liver Disease Based on Network Pharmacology].
    Zuo C; Sun DL; Zhao TH; Wang JJ; Zhang ZZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):253-261. PubMed ID: 35538760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
    Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
    PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
    Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice.
    Kondo K; Sugioka T; Tsukada K; Aizawa M; Takizawa M; Shimizu K; Morimoto M; Suematsu M; Goda N
    Adv Exp Med Biol; 2010; 662():77-82. PubMed ID: 20204774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
    Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
    Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.